These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 32941011)

  • 1. Binding Characterization of GPCRs-Modulator by Molecular Complex Characterizing System (MCCS).
    Feng Z; Liang T; Wang S; Chen M; Hou T; Zhao J; Chen H; Zhou Y; Xie XQ
    ACS Chem Neurosci; 2020 Oct; 11(20):3333-3345. PubMed ID: 32941011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Silico Prediction and Validation of CB2 Allosteric Binding Sites to Aid the Design of Allosteric Modulators.
    Yuan J; Jiang C; Wang J; Chen CJ; Hao Y; Zhao G; Feng Z; Xie XQ
    Molecules; 2022 Jan; 27(2):. PubMed ID: 35056767
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How Do Modulators Affect the Orthosteric and Allosteric Binding Pockets?
    Chen CJ; Jiang C; Yuan J; Chen M; Cuyler J; Xie XQ; Feng Z
    ACS Chem Neurosci; 2022 Apr; 13(7):959-977. PubMed ID: 35298129
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist.
    Pandey P; Roy KK; Doerksen RJ
    J Biomol Struct Dyn; 2020 Jan; 38(1):32-47. PubMed ID: 30652534
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of Mixed-Solvent Molecular Dynamics Simulations for Prediction of Allosteric Sites on G Protein-Coupled Receptors.
    Chan WKB; Carlson HA; Traynor JR
    Mol Pharmacol; 2023 May; 103(5):274-285. PubMed ID: 36868791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct Binding Mechanisms for Allosteric Sodium Ion in Cannabinoid Receptors.
    Dutta S; Selvam B; Shukla D
    ACS Chem Neurosci; 2022 Feb; 13(3):379-389. PubMed ID: 35019279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leveraging allostery to improve G protein-coupled receptor (GPCR)-directed therapeutics: cannabinoid receptor 1 as discovery target.
    Janero DR; Thakur GA
    Expert Opin Drug Discov; 2016 Dec; 11(12):1223-1237. PubMed ID: 27712124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small Molecule Allosteric Modulators of G-Protein-Coupled Receptors: Drug-Target Interactions.
    Lu S; Zhang J
    J Med Chem; 2019 Jan; 62(1):24-45. PubMed ID: 29457894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Allosteric modulation of GPCRs: From structural insights to in silico drug discovery.
    Persechino M; Hedderich JB; Kolb P; Hilger D
    Pharmacol Ther; 2022 Sep; 237():108242. PubMed ID: 35863587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Covalent allosteric modulation: An emerging strategy for GPCRs drug discovery.
    Bian Y; Jun JJ; Cuyler J; Xie XQ
    Eur J Med Chem; 2020 Nov; 206():112690. PubMed ID: 32818870
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allosteric modulators of G-protein-coupled receptors.
    May LT; Christopoulos A
    Curr Opin Pharmacol; 2003 Oct; 3(5):551-6. PubMed ID: 14559102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Modeling Study of a Receptor-Orthosteric Ligand-Allosteric Modulator Signaling Complex.
    Jiang C; He X; Wang Y; Chen CJ; Othman Y; Hao Y; Yuan J; Xie XQ; Feng Z
    ACS Chem Neurosci; 2023 Feb; 14(3):418-434. PubMed ID: 36692197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Strategies for the identification of allosteric modulators of G-protein-coupled receptors.
    Burford NT; Watson J; Bertekap R; Alt A
    Biochem Pharmacol; 2011 Mar; 81(6):691-702. PubMed ID: 21184747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Negative allosteric modulators of cannabinoid receptor 1: Ternary complexes including CB1, orthosteric CP55940 and allosteric ORG27569.
    Aderibigbe AO; Pandey P; Doerksen RJ
    J Biomol Struct Dyn; 2022 Aug; 40(13):5729-5747. PubMed ID: 33480332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational Advances for the Development of Allosteric Modulators and Bitopic Ligands in G Protein-Coupled Receptors.
    Feng Z; Hu G; Ma S; Xie XQ
    AAPS J; 2015 Sep; 17(5):1080-95. PubMed ID: 25940084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Annotation of Allosteric Compounds to Enhance Bioactivity Modeling for Class A GPCRs.
    Burggraaff L; van Veen A; Lam CC; van Vlijmen HWT; IJzerman AP; van Westen GJP
    J Chem Inf Model; 2020 Oct; 60(10):4664-4672. PubMed ID: 32931270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MCCS, a novel characterization method for protein-ligand complex.
    Chen M; Feng Z; Wang S; Lin W; Xie XQ
    Brief Bioinform; 2021 Jul; 22(4):. PubMed ID: 33051641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orthosteric/allosteric bitopic ligands: going hybrid at GPCRs.
    Valant C; Sexton PM; Christopoulos A
    Mol Interv; 2009 Jun; 9(3):125-35. PubMed ID: 19592673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Membrane Lipids Are an Integral Part of Transmembrane Allosteric Sites in GPCRs: A Case Study of Cannabinoid CB1 Receptor Bound to a Negative Allosteric Modulator, ORG27569, and Analogs.
    Obi P; Natesan S
    J Med Chem; 2022 Sep; 65(18):12240-12255. PubMed ID: 36066412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Allosteric modulation of G protein-coupled receptors.
    May LT; Avlani VA; Sexton PM; Christopoulos A
    Curr Pharm Des; 2004; 10(17):2003-13. PubMed ID: 15279541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.